• Corpus ID: 9606247

Investigation of granulomatous prostatitis incidence following intravesical BCG therapy.

@article{Balasar2014InvestigationOG,
  title={Investigation of granulomatous prostatitis incidence following intravesical BCG therapy.},
  author={Mehmet Balasar and Metin Doğan and Abdulkadir Kandemir and Hakan Hakkı Taşkapu and Faruk Çiçekçi and Hatice Toy and Recai Gurbuz},
  journal={International journal of clinical and experimental medicine},
  year={2014},
  volume={7 6},
  pages={
          1554-7
        }
}
UNLABELLED In the present manuscript, we studied the incidence of granulomatous prostatitis in the prostatectomy specimen of the patients who underwent transurethral resection of the prostate (TURP) after superficial bladder cancer treatment with intravesical Bacillus Calmette-Guerin (BCG) and were diagnosed with benign prostate hyperplasia (BPH). The clinical data and histopathological specimen records of 472 patients who underwent TUR-P due to BPH diagnosis, obtained over a period of 6 years… 

Figures and Tables from this paper

Granulomatous Prostatitis After Intravesical Bacillus Calmette-Guérin Instillation Therapy: A Potential Cause of Incidental F-18 FDG Uptake in the Prostate Gland on F-18 FDG PET/CT in Patients with Bladder Cancer
TLDR
BCG-induced granulomatous prostatitis can be a potential cause of benign F-18 FDG uptake, especially in those with a history of bladder cancer treated with BCG, and the intensity of prostate uptake is decreased on the follow-up PET/CT without any treatment.
[Bladder Rupture during Intravesical BCG Therapy : A Case Report].
TLDR
Thinning ofthe bladder wall, delayed wound healing caused by 2 TURs, and abdominal pressure may have been the factors leading to the bladder rupture in addition to inflammation of the bladder due to BCG instillation.
Managing the adverse events of intravesical bacillus Calmette–Guérin therapy
TLDR
Recommendations on the management of complications arising from intravesical treatment with bacillus Calmette–Guérin (BCG) for nonmuscle-invasive bladder tumors are provided.
Clinical Spectrum of Complications Induced by Intravesical Immunotherapy of Bacillus Calmette-Guérin for Bladder Cancer
TLDR
The literature on the potential complications after intravesical BCG immunotherapy for bladder cancer is reviewed and an overview on the incidence, diagnosis, and treatment modality of genitourinary and systemic BCG-induced complications is provided.
Intravesical-BCG as an Unusual Cause of Elevated PSA Leading to an Elusive Diagnosis
  • Medicine
  • 2021
TLDR
In recent times mpMRI become an important tool to determine the need for prostate biopsy in cases of biochemical or clinical suspicion for CaP, and it seems that histological granulomatous prostatitis occurs frequently after BCG instillations as demonstrated on 75% of 119 cases.
Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy
TLDR
Asymptomatic abnormal prostate findings incidentally detected by CT after BCG therapy are not rare, and these disappear over time during the follow-up period without any treatment.
Analysis of risk factors for post-bacillus Calmette–Guerin-induced prostatitis in patients with non-muscle invasive bladder cancer
TLDR
Body mass index and prostate volume may be clinical predictors of prostate lesions after bacillus Calmette–Guerin exposure.
Comparison of Abnormal Prostate MRI and Histopathology of Prostatic Biopsy after Intravesical BCG Therapy for Non-Muscle Invasive Bladder Cancer
TLDR
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially.
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Granulomatous prostatitis on needle biopsy.
TLDR
While NSGP is the most common granulomatous prostatitis seen on needle biopsy, bacillus Calmette-Guerin granulomas are not seen infrequently and may also histologically mimic carcinoma.
Toxicity of intravesical BCG and its management in patients with superficial bladder tumors
TLDR
Toxicity of bacillus Calmette‐Guerin (BCG) Pasteur strain, given in a dose of 120 mg once a week for 6 weeks, was retrospectively evaluated in a study of 107 patients with recurrent superficial bladder cancer, suggesting that immunosuppression is a relative contraindication to BCG use.
The clinical spectrum of granulomatous prostatitis: a report of 200 cases.
Disseminated Mycobacterium bovis after intravesicular bacillus calmette-Gu rin treatments for bladder cancer.
TLDR
A case of disseminated BCG infection causing pneumonitis that required corticosteroids and antitubercular therapy for cure is reported, and it is reported that the majority of patients tolerate BCG intravesicular treatments well.
Peritoneal tuberculosis and granulomatous hepatitis secondary to treatment of bladder cancer with Bacillus Calmette-Guérin
TLDR
In the patient who developed peritonitis, intravesical Bacillus Calmette-Guérin therapy was recommenced after antituberculosis treatment, and completed without further complications.
...
1
2
...